Stage distribution at first and repeat examinations in breast cancer screening
- PMID: 10572843
- DOI: 10.1136/jms.6.3.132
Stage distribution at first and repeat examinations in breast cancer screening
Abstract
Objectives: To investigate observed stage distributions at first and repeat screenings. To compare the observed outcomes with expected values based on simulation modelling, varying the assumptions about the natural history of the disease.
Methods: An overview is made of observed data on stage distribution at first and repeat screenings and the difference between those distributions is summarised in a Gini coefficient. Four possible explanations for the observations are considered, two of these are worked out as Miscan simulation models, and the outcomes are compared with observations.
Results: Often the reported stage distributions at repeat screenings are not or only slightly more favourable than at first screenings and, in the ones that are more favourable, the difference is relatively small. If, in the Miscan model, it is assumed that there is no correlation between the duration of preclinical breast cancer in consecutive tumour size categories and that there is a strong influence of latent cancers, it is not possible to reproduce the observed outcomes.
Conclusions: The two modelled explanations are not sufficient. Decreasing sensitivity seems an unlikely explanation for the discrepancy in many screening programmes. The possibility that the observations may be explained because false reassurance has been given should be seriously considered and investigated.
Similar articles
-
[Diagnostic mode and tumor staging of breast cancers in the setting of opportunistic screenings].Rofo. 2006 Feb;178(2):221-6. doi: 10.1055/s-2005-858760. Rofo. 2006. PMID: 16435254 Clinical Trial. German.
-
The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods.J Natl Cancer Inst Monogr. 2006;(36):47-55. doi: 10.1093/jncimonographs/lgj008. J Natl Cancer Inst Monogr. 2006. PMID: 17032894
-
Breast cancer screening: evidence for false reassurance?Int J Cancer. 2008 Aug 1;123(3):680-6. doi: 10.1002/ijc.23540. Int J Cancer. 2008. PMID: 18484587
-
Diversity of model approaches for breast cancer screening: a review of model assumptions by the Cancer Intervention and Surveillance Network (CISNET) Breast Cancer Groups.Stat Methods Med Res. 2004 Dec;13(6):525-38. doi: 10.1191/0962280204sm381ra. Stat Methods Med Res. 2004. PMID: 15587437 Review.
-
Statistical models for cancer screening.Stat Methods Med Res. 1995 Mar;4(1):18-32. doi: 10.1177/096228029500400103. Stat Methods Med Res. 1995. PMID: 7613635 Review.
Cited by
-
Calibration methods used in cancer simulation models and suggested reporting guidelines.Pharmacoeconomics. 2009;27(7):533-45. doi: 10.2165/11314830-000000000-00000. Pharmacoeconomics. 2009. PMID: 19663525 Free PMC article. Review.
-
Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia.Med Decis Making. 2018 Apr;38(1_suppl):54S-65S. doi: 10.1177/0272989X17711928. Med Decis Making. 2018. PMID: 29554469 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical